Details for Patent: 10,391,160

Which drugs does patent 10,391,160 protect, and when does it expire?

Patent 10,391,160 protects TECFIDERA and is included in one NDA.

This patent has twelve patent family members in six countries.

Summary for Patent: 10,391,160

Title:	Dimethyl fumarate and vaccination regimens
Abstract:	Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.
Inventor(s):	Viglietta; Vissia (Boston, MA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	15/125,612
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 10,391,160

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-001	Mar 27, 2013	AB	RX	Yes	No						METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE
Biogen Inc	TECFIDERA	dimethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	204063-002	Mar 27, 2013	AB	RX	Yes	Yes						METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE

Foreign Priority and PCT Information for Patent: 10,391,160

PCT Information
PCT Filed	March 13, 2015	PCT Application Number:	PCT/US2015/020470
PCT Publication Date:	September 17, 2015	PCT Publication Number:	WO2015/138917

International Family Members for US Patent 10,391,160

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016244325
Australia	2018229422
Australia	2020213345